Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review
- 868 Downloads
Hydroxyethyl starch solutions (HES) are plasma volume expanders which affect hemostasis. Newer HES 130/0.4 is said to be safer. Reevaluation of published evidence is necessary after the recent retraction of studies.
Systematic review of studies assessing HES 130/0.4 effects on hemostasis by thrombelastography (TEG, ROTEM) or Sonoclot (SCR) in comparison with crystalloid or albumin control fluids was performed. Only studies which provided statistical comparisons between study fluids were analyzed. Studies were divided into in vitro or in vivo hemodilution studies. We assessed study quality, HES effects which differed significantly from controls, values outside normal range, degree of hemodilution, and cumulative HES dose.
Seventeen in vitro and seven in vivo hemodilution studies were analyzed. Four studies reported quality control measures.
Nineteen studies (all 15 ROTEM studies, 3 of 5 in vitro TEG, and 1 of 2 SCR studies) showed a significant hypocoagulatory effect of HES 130/0.4 on clot formation, while clotting time was not uniformly affected. Three in vivo TEG studies with low HES doses or cancer patients found mixed or nonsignificant results. In studies which provided normal ranges (n = 9), more values were outside normal ranges in the HES than in the control groups (87/122 vs. 58/122, p < 0.001). Dose effects were apparent in the in vitro studies, which investigated higher dilutions up to 80%. In vivo studies were fewer and did not investigate doses >40 ml/kg.
HES 130/0.4 administration results in a weaker and smaller clot. Until results from well-designed clinical trials are available, safer fluids should be chosen for patients with impaired coagulation.
KeywordsPlasma volume expanders Thrombelastography Coagulopathy Colloids
The authors gratefully acknowledge the contributions of Dr. Shasha Chen for Chinese language translation and of Prof. Don Bredle for English language editing. Support was provided solely from institutional and/or departmental sources.
Conflict of Interest
C.S.H. and D.R. declare no conflicts of interest. W.L. has in the past received study support, honoraria, and travel funding from CSL Behring, Germany and Pentapharm Germany. M.H. received speaker fees and travel costs from CSL Behring. K.R. has in the past received consultancy fees from B. Braun Melsungen.
- 10.Afshari A, Wikkelso A, Brok J, Moller A, Wetterslev J (2009) Thrombelastography (TEG) or Thrombelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion (Protocol). Cochrane database of systematic reviews (Online):CD007871Google Scholar
- 12.Editors-in-Chief Statement Regarding IRB Approval of Clinical Trials by Joachim Boldt. http://www.aaeditor.org/EICJointStatement.pdf; assessed 16 Feb 2011 DOI
- 14.Reitsma JB, Rutjes AWS, Whiting P, Vlassov VV, Leeflang MMG, Deeks JJ, (2009. Available from: http://srdta.cochrane.org/.) Chapter 9: assessing methodological quality. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 100 DOI
- 15.Fries D, Innerhofer P, Klingler A, Berresheim U, Mittermayr M, Calatzis A, Schobersberger W (2002) The effect of the combined administration of colloids and lactated Ringer’s solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis (ROTEG). Anesth Analg 94:1280–1287PubMedCrossRefGoogle Scholar
- 21.Casutt M, Kristoffy A, Schuepfer G, Spahn DR, Konrad C (2010) Effects on coagulation of balanced (130/0.42) and non-balanced (130/0.4) hydroxyethyl starch or gelatin compared with balanced Ringer’s solution: an in vitro study using two different viscoelastic coagulation tests ROTEMTM and SONOCLOTTM. Br J Anaesth 105:273–281PubMedCrossRefGoogle Scholar
- 31.Felfernig M, Franz A, Braunlich P, Fohringer C, Kozek-Langenecker SA, Felfernig M, Franz A, Braunlich P, Fohringer C, Kozek-Langenecker SA (2003) The effects of hydroxyethyl starch solutions on thromboelastography in preoperative male patients. Acta Anaesthesiol Scand 47:70–73PubMedCrossRefGoogle Scholar
- 32.Jin SL, Yu BW (2010) Effects of acute hypervolemic fluid infusion of hydroxyethyl starch and gelatin on hemostasis and possible mechanisms. Clin Appl Thromb Hemost 16:91–98Google Scholar
- 33.James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS (2011) Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth. doi:10.1093/bja/aer229
- 36.Bang SR, Kim YH, Kim GS (2010) The effects of in vitro hemodilution with 6% hydroxyethyl starch (HES) (130/0.4) solution on thrombelastograph analysis in patients undergoing liver transplantation. Clin Transplant 25:450–456Google Scholar
- 41.Brinkman AC, Romijn JW, van Barneveld LJ, Greuters S, Veerhoek D, Vonk AB, Boer C (2010) Profound effects of cardiopulmonary bypass priming solutions on the fibrin part of clot formation: an ex vivo evaluation using rotation thromboelastometry. J Cardiothorac Vasc Anesth 24:422–426PubMedCrossRefGoogle Scholar
- 44.Sossdorf M, Appelt A, Schaarschmidt B, Döring S, Claus RA, Hartog C, Lösche W (2008) Hydroxyethyl starch solutions impair clot formation and platelet aggregation but enhance platelet surface receptor expression. Hämatologie 28:A82Google Scholar
- 47.Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koepf M, Innerhofer P (2007) Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 105:905–917PubMedCrossRefGoogle Scholar